HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Coadministration With Carbidopa Enhances the Antimyopic Effects of Levodopa in Chickens.

AbstractPurpose:
Topical application of levodopa inhibits the development of form-deprivation myopia (FDM) and lens-induced myopia (LIM) in chicks. Here we examine whether coadministration with carbidopa enhances this protection and compare the effectiveness of topical versus systemic administration. We also investigate the degree to which topical and systemic administration of these compounds alters retinal dopamine release and examine whether this is the mechanism by which they inhibit experimental myopia.
Methods:
Levodopa and levodopa:carbidopa (at a 4:1 ratio) were administered as twice-daily eye drops or once-daily intraperitoneal injections to chicks developing FDM or LIM over an ascending dose range. Axial length and refraction were measured following 4 days of treatment. Dopamine levels in the vitreous and blood were analyzed using liquid chromatography-mass spectrometry following topical or systemic administration of levodopa or levodopa:carbidopa. Finally, chicks receiving topical or systemic levodopa or levodopa:carbidopa were cotreated with the dopamine antagonist spiperone.
Results:
Levodopa:carbidopa inhibited the development of FDM and LIM to a greater extent than levodopa alone (P < 0.05). Topical application was more effective than systemic administration (P < 0.001). Vitreal dopamine levels were increased to the greatest extent by topical application of levodopa:carbidopa (P < 0.001). Systemic but not topical administration significantly increased dopamine levels within the blood (P < 0.01). Cotreatment with spiperone inhibited the antimyopic effects (P < 0.05) of levodopa and levodopa:carbidopa.
Conclusions:
The presence of carbidopa increases the bioavailability of levodopa within the eye, enhancing its antimyopic effects, with topical application showing the greatest efficacy. Thus levodopa:carbidopa may be a promising treatment for controlling the progression of human myopia.
AuthorsKate Thomson, Ian Morgan, Tamsin Kelly, Cindy Karouta, Regan Ashby
JournalInvestigative ophthalmology & visual science (Invest Ophthalmol Vis Sci) Vol. 62 Issue 4 Pg. 25 (04 01 2021) ISSN: 1552-5783 [Electronic] United States
PMID33877264 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers
  • Dopamine Agents
  • Drug Combinations
  • Ophthalmic Solutions
  • carbidopa, levodopa drug combination
  • Levodopa
  • Carbidopa
  • Dopamine
Topics
  • Administration, Topical
  • Animals
  • Animals, Newborn
  • Biomarkers (metabolism)
  • Carbidopa (administration & dosage)
  • Chickens
  • Disease Models, Animal
  • Dopamine (metabolism)
  • Dopamine Agents (administration & dosage)
  • Dose-Response Relationship, Drug
  • Drug Combinations
  • Injections, Intraperitoneal
  • Levodopa (administration & dosage)
  • Male
  • Mitosis (drug effects)
  • Myopia (drug therapy, metabolism, pathology)
  • Ophthalmic Solutions
  • Sensory Deprivation
  • Vitreous Body (metabolism, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: